Saturday 17 October 2026
Export MIST’s income statement to Excel — free account
Milestone Pharmaceuticals Inc.
MIST Healthcare Biotechnology
Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023. In the quarter to June 2026, revenue fell 62.7%, EPS fell 5.00%, free cash flow fell 80.8% and total debt rose 7.19%, each against the same quarter a year earlier.
0.71
0.09
−11.25%
Follow MIST
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 1 | — | — |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Altman Z-Score |
— | — | — | — | 20.31 | 5.87 | (6.95) | — | (4.65) |
P/S ratio |
— | — | — | — | 0.00 | 0.00 | 3.68 | — | 8.07 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 14.38 | (2.69) | (13.55) | — | (9.77) |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Beneish M-Score |
— | — | — | — | — | 15.89 | 9.07 | — | — |
P/Operating CF |
— | — | — | — | (22.14) | (13.37) | (7.89) | — | (13.26) |
P/B ratio |
— | — | — | — | 2.43 | 2.59 | 4.61 | — | 4.06 |
Price to Tangible BV |
— | — | — | — | 2.43 | 2.59 | 4.61 | — | 4.06 |
EV/Sales |
— | — | — | — | 0.00 | 0.00 | 2.91 | — | 5.75 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
EV/Operating CF |
— | — | — | — | (4.83) | (2.08) | (1.32) | — | (2.46) |
EV/FCF |
— | — | — | — | (4.77) | (2.07) | (1.31) | — | (2.45) |
Quick Ratio |
16.84 | 19.05 | 14.42 | 23.14 | 16.87 | 10.66 | 9.58 | 8.76 | 7.81 |
Current Ratio |
17.17 | 19.42 | 14.71 | 24.14 | 17.55 | 11.70 | 10.11 | 9.10 | 8.01 |
Net Debt/EBITDA |
3.26 | 3.61 | 2.07 | 2.80 | 2.64 | 1.05 | 0.27 | 0.39 | 0.79 |
Debt/Assets |
0.00% | 0.00% | 0.15% | 0.46% | 0.40% | 2.68% | 66.16% | 70.67% | 50.36% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 2.97 | 4.06 | 1.37 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.05 | 0.01 | 0.00 | 0.02 |
Operating CF/Net income |
1.00 | 0.91 | 0.93 | 1.02 | 0.78 | 0.90 | 0.78 | 0.69 | 0.78 |
Capex/Depreciation |
(4.50) | (0.50) | (10.87) | 0.00 | 0.00 | (3.06) | (1.22) | (0.31) | (2.65) |
Interest Coverage |
(44.45) | (33.50) | (22.30) | (69.85) | (195.79) | (47.56) | (23.92) | (11.76) | (16.19) |
| 18.31% | 52.50% | (185.00%) | (38.73%) | (33.52%) | (65.26%) | (143.61%) | (277.55%) | (229.65%) | |
| (13.98%) | (40.09%) | (52.22%) | (36.55%) | (31.76%) | (60.09%) | (79.73%) | (55.09%) | (66.71%) | |
ROIC |
0.00% | 0.00% | 0.00% | (2,105.90%) | 0.00% | (991.65%) | (7,071.53%) | 0.00% | 0.00% |
Return on Tangible Assets |
(31.12%) | (27.75%) | (48.20%) | (34.98%) | (38.14%) | (88.57%) | (90.32%) | (62.91%) | (64.05%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 3.09 | 64.39 | 1,170.92 | 0.00 | 753.61 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 257.81% | 796.58% | 3,105.20% | 0.00% | 1,171.28% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 82.66% | 314.36% | 1,593.20% | 0.00% | 1,117.34% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 48.53% | 180.96% | 953.40% | 0.00% | 482.60% |
Graham Net Nets |
— | — | — | — | 0.41 | 0.37 | 0.19 | — | 0.24 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Earnings Yield |
— | — | — | — | (15.57%) | (33.83%) | (77.22%) | — | (39.11%) |
Free Cash Flow Yield |
— | — | — | — | (12.28%) | (30.74%) | (60.19%) | — | (29.12%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.12 | 0.02 | 0.00 | 0.02 |
Operating CF per Share |
(34.00) | (65.93) | (3.24) | (1.73) | (0.79) | (1.24) | (1.08) | (0.46) | (0.58) |
Capex per Share |
(0.15) | (0.02) | (0.03) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(34.16) | (65.95) | (3.27) | (1.73) | (0.79) | (1.24) | (1.08) | (0.46) | (0.59) |
Cash per Share |
113.65 | 269.35 | 7.59 | 4.85 | 2.73 | 1.52 | 1.54 | 1.12 | 1.26 |
Shareholders Equity per Share |
(139.86) | (172.96) | 7.28 | 4.88 | 2.69 | 1.56 | 0.39 | 0.21 | 0.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(139.86) | (172.96) | 7.28 | 4.88 | 2.69 | 1.56 | 0.39 | 0.21 | 0.50 |
Free Cash Flow |
(8.09) | (21.05) | (51.56) | (50.73) | (33.22) | (52.74) | (46.54) | (28.88) | (49.34) |
Working Capital |
25.95 | 83.52 | 114.17 | 142.53 | 112.15 | 65.66 | 65.81 | 65.80 | 97.94 |
Capital Expenditures |
(0.04) | 0.00 | (0.41) | — | — | (0.27) | (0.11) | (0.03) | (0.30) |
Net Current Asset Value |
(33.15) | (55.24) | 113.99 | 141.83 | 111.67 | 63.67 | 14.58 | 11.57 | 40.13 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.05 | 0.11 | 0.00 | 0.20 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.23 | 0.33 | 0.09 | 0.31 | 0.43 | 0.35 | 0.33 | 0.53 | 0.22 |
Cash ROIC |
130.30% | (68.42%) | (21.95%) | (17.73%) | (14.62%) | (39.68%) | (35.11%) | (21.21%) | (24.08%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 85.71 | 9.91 | 0.49 | 0.00 | 0.66 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 |
Average Receivables |
0.61 | 0.25 | 0.32 | 0.24 | 0.18 | 0.50 | 2.05 | 2.35 | 2.34 |
Average Payables |
3.04 | 3.04 | 6.24 | 6.96 | 6.23 | 6.10 | 6.16 | 7.12 | 10.42 |
Average Assets |
57.84 | 57.84 | 105.75 | 136.70 | 134.91 | 97.17 | 74.85 | 75.36 | 94.53 |
Average Common Equity |
(44.16) | (44.16) | 29.85 | 129.02 | 127.86 | 89.47 | 41.56 | 14.96 | 27.46 |
Columns are period end dates